Lacosamida Alembic (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This action stabilizes hyperexcitable neuronal membranes, reducing repetitive firing that can trigger seizures, while preserving normal neuronal conduction.

The dosage of Lacosamida Alembic is individualized and set by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for lacosamide in pregnancy and lactation are limited. The medication should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from agents like carbamazepine or phenytoin, which target fast inactivation. This can result in a distinct side‑effect profile and may be advantageous for patients who have not responded well to other sodium‑channel blockers.

Lacosamida Alembic should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

The medication is taken orally, usually as a tablet, and should be swallowed whole with water. It is typically administered once or twice daily as directed by the prescriber, with dosing times adjusted to the patient’s routine for optimal adherence.

Serious adverse events can include cardiac arrhythmias such as supraventricular tachycardia, severe skin reactions like Stevens‑Johnson syndrome, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms such as palpitations, rash, or jaundice.

Individuals with known hypersensitivity to lacosamide or any component of the formulation should avoid the product. Patients with severe cardiac conduction disorders, uncontrolled arrhythmias, or significant hepatic impairment should not use it without careful medical evaluation.